'Quiet' FDA panel rejects QRxPharma's opioids combo MoxDuo
This article was originally published in Scrip
Executive Summary
Even though an FDA panel of advisers unanimously rejected QRxPharma's morphine/oxycodone combination drug MoxDuo as a treatment for patients with moderate-to-severe acute pain over the product's individual components or other single-entity opioids, the expert advisers gave little insight into what they were thinking.